{Reference Type}: Journal Article
{Title}: Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article.
{Author}: Hussain M;Yellapragada S;Al Hadidi S;
{Journal}: Blood Lymphat Cancer
{Volume}: 13
{Issue}: 0
{Year}: 2023
暂无{DOI}: 10.2147/BLCTT.S272703
{Abstract}: Multiple myeloma (MM) is a hematologic malignancy characterized by the abnormal clonal proliferation of plasma cells that may result in focal bone lesions, renal failure, anemia, and/or hypercalcemia. Recently, the diagnosis and treatment of MM have evolved due to a better understanding of disease pathophysiology, improved risk stratification, and new treatments. The incorporation of new drugs, including proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies and high-dose chemotherapy followed by hematopoietic stem cell transplantation, has resulted in a significant improvement in patient outcomes and QoL. In this review, we summarize differential diagnoses and therapeutic advances in MM.